Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Amortization of Deferred Charges: 2020-2024

Historic Amortization of Deferred Charges for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $6.3 million.

  • Oncology Institute's Amortization of Deferred Charges fell 2615.0% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 9216.91%. This contributed to the annual value of $6.3 million for FY2024, which is 161.16% up from last year.
  • According to the latest figures from FY2024, Oncology Institute's Amortization of Deferred Charges is $6.3 million, which was up 161.16% from $6.2 million recorded in FY2023.
  • In the past 5 years, Oncology Institute's Amortization of Deferred Charges registered a high of $6.3 million during FY2024, and its lowest value of $53000.0 during FY2021.
  • Over the past 5 years, Oncology Institute's median Amortization of Deferred Charges value was $2.4 million (recorded in 2022), while the average stood at $3.0 million.
  • In the last 5 years, Oncology Institute's Amortization of Deferred Charges plummeted by 1166.67% in 2021 and then surged by 451132.08% in 2022.
  • Over the past 5 years, Oncology Institute's Amortization of Deferred Charges (Annual) stood at $60000.0 in 2020, then dropped by 11.67% to $53000.0 in 2021, then surged by 4511.32% to $2.4 million in 2022, then surged by 153.89% to $6.2 million in 2023, then increased by 1.61% to $6.3 million in 2024.
  • Its Amortization of Deferred Charges stands at $6.3 million for FY2024, versus $6.2 million for FY2023 and $2.4 million for FY2022.